Xin Rui
, 41 Xibei Street
Ningbo, 315010, China
Ningbo, 315010, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Research progress on the reduction of albic soil obstacles.
Journal: Ying yong sheng tai xue bao = The journal of applied ecology
Published: December 25, 2025
Correspondence on "METTL3 promotes an immunosuppressive microenvironment in bladder cancer via m6A-dependent CXCL5/CCL5 regulation" by Tong et al.
Journal: Journal for immunotherapy of cancer
Published: May 17, 2025
Re: Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial. Eur Urol. 2025;88:23-30.
Journal: European urology
Published: May 11, 2025
Comment on "Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT)".
Journal: Journal for immunotherapy of cancer
Published: March 24, 2025
Formation Mechanisms of Protein Coronas on Food-Related Nanoparticles: Their Impact on Digestive System and Bioactive Compound Delivery.
Journal: Foods (Basel, Switzerland)
Published: December 29, 2024
Fatty acid metabolism-derived prognostic model for lung adenocarcinoma: unraveling the link to survival and immune response.
Journal: Frontiers in immunology
Published: October 08, 2024
Prognostic value of miR-339-5p in patients with prostate cancer and its effects on tumor progression.
Journal: Experimental and therapeutic medicine
Published: March 05, 2020
Identification of recurrence marker associated with immune infiltration in prostate cancer with radical resection and build prognostic nomogram.
Journal: BMC cancer
Published: June 19, 2019
Evaluation of PD-L1 biomarker for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatments for urothelial carcinoma patients: A meta-analysis.
Journal: International immunopharmacology
Published: September 09, 2018
LncRNA GAS6-AS2 promotes bladder cancer proliferation and metastasis via GAS6-AS2/miR-298/CDK9 axis.
LncRNA GAS6-AS2 promotes bladder cancer proliferation and metastasis via GAS6-AS2/miR-298/CDK9 axis.
Journal: Journal of cellular and molecular medicine
Published: June 19, 2018
Last Updated: 09/26/2026